Ribaldone, D.G.; Caviglia, G.P.; Abdulle, A.; Pellicano, R.; Ditto, M.C.; Morino, M.; Fusaro, E.; Saracco, G.M.; Bugianesi, E.; Astegiano, M.
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease. J. Clin. Med. 2019, 8, 1646.
https://doi.org/10.3390/jcm8101646
AMA Style
Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M.
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease. Journal of Clinical Medicine. 2019; 8(10):1646.
https://doi.org/10.3390/jcm8101646
Chicago/Turabian Style
Ribaldone, Davide Giuseppe, Gian Paolo Caviglia, Amina Abdulle, Rinaldo Pellicano, Maria Chiara Ditto, Mario Morino, Enrico Fusaro, Giorgio Maria Saracco, Elisabetta Bugianesi, and Marco Astegiano.
2019. "Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease" Journal of Clinical Medicine 8, no. 10: 1646.
https://doi.org/10.3390/jcm8101646
APA Style
Ribaldone, D. G., Caviglia, G. P., Abdulle, A., Pellicano, R., Ditto, M. C., Morino, M., Fusaro, E., Saracco, G. M., Bugianesi, E., & Astegiano, M.
(2019). Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease. Journal of Clinical Medicine, 8(10), 1646.
https://doi.org/10.3390/jcm8101646